Clinical trials: Essential Hypertension.
Hypertension
Effect of the Fixed Dose Combination Amlodipine/Valsartan on Central Aortic Blood Pressure in Uncontrolled Essential Hypertension With Amlodipine 5 mg
Assess that for an equivalent brachial blood pressure (BP)lowering, a fixed dose combination amlodipine/valsartan based regimen reduces central aortic BP pressure to a larger extent than an atenolol/amlodipine combination based…
- Trial name
- EXPLOR (NCT00687973)
- Testing
- Valsartan/amlodipine 80/5 mg tablets, Amlodipine 5 mg capsules, Amlodipine 10 mg capsules
- Where
- France
- Volunteers
- 393 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
CKD-828 S-Amlodipine Non-Responder Trial
The aim of present study is to evaluate the efficacy and safety of two dose combination of S-Amlodipine/Telmisartan (2.5/40mg amd 2.5/80mg) compared with S-Amlodipine monotherapy (2.5mg) in hypertensive patients inadequately…
- Trial name
- NCT01501253
- Testing
- CKD-828 2.5/40mg, CKD-828 2.5/80mg, S-Amlodipine 2.5mg
- Where
- South Korea
- Volunteers
- 187 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertension
A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension
A multicenter, randomized, double-blind, parallel, phase 2 study to explore the dose of HCP1803 in patients with essential hypertension
- Trial name
- HM_APOLLO (NCT04959305)
- Testing
- HCP1803-3, RLD2003, RLD2004
- Where
- South Korea
- Volunteers
- 245 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Hypertension
Clinical Efficacy and Safety Evaluation of HCP1904-1 in Essential Hypertension Patients
The purpose of this study is to evaluate of efficacy and safety of HCP1904-1 and RLD2001-1 alone in patients with essential hypertension inadequately controlled on RLD2001-1 monotherapy.
- Trial name
- NCT04820907
- Testing
- HCP1904-1, RLD2001-1
- Where
- South Korea
- Volunteers
- 123 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Hypertension
Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Hypertension Patients
The purpose of this study is to evaluate the antihypertensive efficacy and safety of Fimasartan (BR-A-657•K) 60 mg~120 mg in patients with mild to moderate essential hypertension.
- Trial name
- NCT00922480
- Testing
- Fimasartan, Losartan (Control)
- Volunteers
- 506 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Diseases of the Circulatory System, Essential Hypertension
To Evaluate the Drug-drug Interaction Between Telmisartan and Atorvastatin in Healthy Male Volunteers
The study design was composed of 2 parts, 2-way crossover and multiple-dose. There are having 2 groups in each part that have divided period 1 and period 2, and wash-out period is 16 days between periods.
- Trial name
- NCT02579356
- Testing
- Telmisartan, Atorvastatin
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Samil Pharmaceutical Co., Ltd.
Hypertension
A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren 150mg, 300mg, and 600mg to Placebo in Patients With High Blood Pressure.
Evaluate the blood pressure lowering effect of aliskiren 150mg, 300mg and 600mg compared to placebo in patients with essential hypertension
- Trial name
- NCT00219128
- Testing
- aliskiren
- Where
- United States
- Volunteers
- 671 people
- Sponsor
- Novartis
Hypertension
Compare Effectiveness of Eplerenone vs Atenolol in Reversing the Remodelling Resistance Arteries in Subjects With HT
To investigate the impact of antihypertensive therapy with the selective mineralocorticoid receptor blocker, eplerenone, on small resistance artery remodeling, compared to the effect of equivalent blood pressure control achieved…
- Trial name
- NCT00147563
- Testing
- Eplerenone
- Where
- Canada
- Volunteers
- 34 people
- Sponsor
- Pfizer
Hypertension
Long Term Study of VAH631 in Patients With Essential Hypertension (Extension From B1303 Study)
This study is designed to provide long-term safety and efficacy data for the combination doses of VAH (VAL/ HCTZ) 40/6.25mg and 80/12.5mg in essential hypertensive patients.
- Trial name
- NCT00338936
- Testing
- Valsartan + Hydrochlorothiazide
- Volunteers
- 362 people
- Sponsor
- Novartis
Essential Hypertension
Fimasartan (BR-A-657) Multiple Oral Dose in Healthy Subjects
The objective of this study is to determine the safety and tolerability and to determine the Pharmacokinetic and Pharmacodynamic(PK/PD) of ascending multiple oral dose of BR-A-657 in healthy male subjects.
- Trial name
- NCT01289899
- Testing
- BR-A-657
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Subjects With Stage 1 or 2 Essential Hypertension
The primary objective of the study is to evaluate the safety and tolerability of single ascending doses of Vasomera (PB1046) administered subcutaneously in adult subjects with Stage 1 or Stage 2 essential hypertension.
- Trial name
- NCT01523067
- Testing
- Vasomera (PB1046), 0.9% Sodium Chloride
- Where
- 5 sites in United States
- Volunteers
- 68 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Essential Hypertension
A Phase III Study to Efficacy and Safety of DWC202405/DWC202313 and DWC202314 in Patients With Hypertension
A Multi-center, Randomized, Double-blind, Parallel design, Phase III study to Evaluate and Compare the Efficacy and Safety of DWC202405/DWC202313 and DWC202314 Combination Therapy to DWC202405/DWC202313 in Patients with Essential…
- Trial name
- NCT06671392
- Testing
- DWC202405, DWC202405, DWC202314, DWC202405, DWC202314P
- Where
- South Korea
- Volunteers
- 198 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Essential Hypertension
Clinical Trial to Evaluate the Efficacy and the Safety of Antihypertensive Tablets
The purpose of this study is to determine the optimal dosage of the clinical trial which is evaluating the antihypertensive efficacy and the safety of OJP-2028 tablets in patients with the uncomplicated essential hypertension.
- Trial name
- NCT00553865
- Testing
- OJP-2028
- Where
- South Korea
- Volunteers
- 120 people
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Essential Hypertension
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 Under Fed Conditions
The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of BR1015 and co-administration of BR1015-3 and BR1015-2 in healthy volunteers under fed conditions
- Trial name
- NCT06744439
- Testing
- BR1015, BR1015-2, BR1015-3
- Where
- South Korea
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Primary Hypertension
Renal Denervation by Iberis MultiElectrode Renal Denervation System in Patients With Primary Hypertension
The purpose of Iberis-HTN trial is to evaluate the safety and effectiveness of renal denervation in subjects with primary hypertension by using Iberis multielectrode renal denervation system
- Trial name
- Iberis-HTN (NCT02901704)
- Testing
- Renal Denervation System (AngioCare)
- Volunteers
- 216 people
- Sponsor
- Shanghai AngioCare Medical
Hypertension
An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension
The purpose of the study is to evaluate the efficacy and safety of the study drug relative to an active comparator losartan which is in the same class of drug and is approved for use in the pediatric population aged 6 years and…
- Trial name
- NCT02235909
- Testing
- Azilsartan Medoxomil Low-dose, Losartan, Azilsartan Medoxomil Medium-dose (20 mg)
- Where
- 69 sites in United States, Argentina and 10 more
- Volunteers
- 377 people
- Sponsor
- Arbor Pharmaceuticals, Inc.
Essential Hypertension
Efficacy of Rostafuroxin in the Treatment of Essential Hypertension
The purpose of this study is to verify the efficacy of Rostafuroxin in the treatment of essential hypertension and to determine the best effective dose to be administered in the general hypertensive population and in a subset of…
- Trial name
- NCT00415038
- Testing
- Rostafuroxin
- Where
- Belgium
- Volunteers
- 438 people
- Sponsor
- sigma-tau i.f.r. S.p.A.
Hypertension, Primary Hypercholesterolaemia
To Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients With Essential Hypertension and Primary Hypercholesterolemia
A Multicenter, Randomized, Double-blind, Active-controlled, Parallel group, Phase 3 trial to Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients with Essential Hypertension and Primary…
- Trial name
- HODO-2224 (NCT06646354)
- Testing
- Ezetimibe/Rosuvastatin/Candesartan/Amlodipine, Candesartan/Amlodipine, Candesartan/Rosuvastatin/Ezetimibe
- Where
- South Korea
- Volunteers
- 125 people
- Sponsor
- Hyundai Pharm
Hypertension
Irbesartan and Amlodipine Combination in Controlling Blood Pressure
The primary objective is to compare the extent of reduction of mean Seated Diastolic Blood Pressure (SeDBP) at the end of 8 weeks between each Fixed Dose Combination (FDC), its individual constituents administered as monotherapy…
- Trial name
- I-COMBO (NCT00950066)
- Testing
- IRBESARTAN (SR47436), Amlodipine, Irbesartan / Amlodipine
- Where
- 4 sites in India, Philippines and 2 more
- Volunteers
- 270 people
- Sponsor
- Sanofi
Hypertension
Safety/Efficacy of Combo Therapy With Aliskiren & Hydrochlorothiazide vs Therapy With Hydrochlorothiazide Alone in Patients With Hypertension
The purpose of this trial is to evaluate the safety and efficacy of combination therapy of aliskiren/hydrochlorothiazide (HCTZ) 150/25 mg and 300/25 mg compared with HCTZ 25 mg in patients with hypertension who do not show…
- Trial name
- NCT00387517
- Testing
- Aliskiren/HCTZ
- Where
- 2 sites in United States, Germany
- Volunteers
- 726 people
- Sponsor
- Novartis